Pacer Advisors Inc. Purchases 484,998 Shares of Fresenius Medical Care AG (NYSE:FMS)

Pacer Advisors Inc. boosted its holdings in shares of Fresenius Medical Care AG (NYSE:FMS) by 14,252.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 488,401 shares of the company’s stock after acquiring an additional 484,998 shares during the period. Pacer Advisors Inc. owned about 0.08% of Fresenius Medical Care worth $10,173,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in FMS. Wetherby Asset Management Inc. lifted its position in shares of Fresenius Medical Care by 9.0% during the first quarter. Wetherby Asset Management Inc. now owns 6,807 shares of the company’s stock valued at $229,000 after buying an additional 560 shares during the last quarter. Comerica Bank acquired a new stake in Fresenius Medical Care in the second quarter valued at approximately $140,000. Signaturefd LLC boosted its stake in Fresenius Medical Care by 7.3% in the third quarter. Signaturefd LLC now owns 8,601 shares of the company’s stock valued at $185,000 after acquiring an additional 584 shares in the last quarter. Morningstar Investment Services LLC grew its holdings in Fresenius Medical Care by 6.4% in the third quarter. Morningstar Investment Services LLC now owns 10,145 shares of the company’s stock worth $220,000 after purchasing an additional 612 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Fresenius Medical Care by 2.6% during the second quarter. Dimensional Fund Advisors LP now owns 24,144 shares of the company’s stock worth $578,000 after purchasing an additional 616 shares in the last quarter. Hedge funds and other institutional investors own 8.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 21st. Morgan Stanley downgraded shares of Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a report on Monday, January 8th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Fresenius Medical Care has a consensus rating of “Hold” and a consensus price target of $32.25.

Fresenius Medical Care Stock Up 2.4 %

Shares of FMS stock opened at $19.36 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.07 and a current ratio of 1.42. Fresenius Medical Care AG has a fifty-two week low of $16.37 and a fifty-two week high of $27.72. The firm has a market capitalization of $11.36 billion, a PE ratio of 21.04, a P/E/G ratio of 0.91 and a beta of 1.00. The stock’s 50-day simple moving average is $19.74 and its 200-day simple moving average is $19.82.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings results on Tuesday, February 20th. The company reported $0.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.11. The company had revenue of $5.37 billion during the quarter, compared to analyst estimates of $5.32 billion. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. Equities analysts expect that Fresenius Medical Care AG will post 1.53 earnings per share for the current year.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.